Vasodilatory shock

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

Retrieved on: 
Thursday, August 18, 2022

Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.

Key Points: 
  • Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.
  • The District Court held that Eagle did not infringe on any of Pars patents, and Par appealed.
  • Oral arguments were held before the Federal Circuit in July 2022.
  • Today, the Federal Circuit issued its decision rejecting Pars arguments and affirming the District Courts finding of non-infringement.

Endpoint Health Announces Results from Retrospective Analyses Evaluating the Corticosteroid Response in Patients with Septic Shock, Based on Novel Gene Expression Scoring Model

Retrieved on: 
Wednesday, March 2, 2022

This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.

Key Points: 
  • This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.
  • These latest findings further illustrate the potential of our proprietary AI and machine learning platform to inform personalized care for critically ill patients, based on electronic health data and gene expression scoring.
  • To identify unique biological subgroups of patients, the researchers conducted a retrospective analysis, pooling publicly available data from various gene expression datasets of patients with sepsis and septic shock.
  • The secondary outcome was the immunological response to hydrocortisone therapy.1 This outcome was assessed based on gene expression data from the Burn study.

Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin

Retrieved on: 
Tuesday, January 18, 2022

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict, with 180 days of marketing exclusivity.

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict, with 180 days of marketing exclusivity.
  • The Eagle team has worked very hard to advance vasopressin for patients in need.
  • On August 31, 2021, the U.S. District Court for the District of Delaware held that Eagles proposed vasopressin product does not infringe any of the patents Par asserted against Eagle.
  • Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise.

DGAP-News: PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY

Retrieved on: 
Friday, July 16, 2021

GIAPREZA(R) is approved by the European Commission for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Key Points: 
  • GIAPREZA(R) is approved by the European Commission for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
  • In 2013, the mortality rate of patients in Germany with severe septic shock was as high as almost 60% [1] .
  • GIAPREZA(R) for infusion is an FDA-approved vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
  • XERAVA(R) is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.